Cystic Fibrosis Drugs Market Expected to Grow with a CAGR of 10% During the Forecast Period, 2019-2025 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 11, 2019--
The “Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of Application (Oral, Inhalation and Intravenous), By Region - Global Forecast up to 2025” report has been added to ResearchAndMarkets.com’s offering.
Overview of the Global Cystic Fibrosis Drugs Market
The author’s market research report predicts that the Global Cystic Fibrosis Drugs Market will grow at a CAGR of more than 10% during the forecast period 2019-2025. The market has witnessed steady growth in the past few years and is sustaining due to rising prevalence of cystic fibrosis diseases, advancements in screening and treatments technology, and high prevalence of tobacco smoking.
Initiatives from government and other organizations, promising pipeline for the treatment of cystic fibrosis, and market expansion opportunities in emerging nations are providing scope for the growth of the cystic fibrosis drugs market. However, complex drug development process and expensive treatment options is restraining the growth of cystic fibrosis market.
Cystic Fibrosis Drugs Market Research Competitive Analysis
Current cystic fibrosis medications are not appropriate for all patients and has restricted impact on this life-threatening disease. But these hurdles can be overcome by new developments of various therapeutic approaches. The development of small molecules for the treatment of cystic fibrosis has made important advancement in the previous decade. However, one of the major issues is that the success in the treatment options has been observed in only certain mutation classes among the 2000 mutations identified. Thus, many patients do not have any treatment.
Key Competitive Facts
The report provides complete details about the sub-segments of the cystic fibrosis drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pure-play companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.
Key Topics Covered:
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition - Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Respiratory Pipeline
4 Market Outlook
4.1 Product Pipeline
4.2 Market Segmentation
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
22.214.171.124 Rising prevalence of cystic fibrosis diseases
126.96.36.199 Advancements in screening and treatments technology
188.8.131.52 High prevalence of tobacco smoking
184.108.40.206 Complex drug development process
220.127.116.11 Expensive treatment options for cystic fibrosis
18.104.22.168 Initiatives from government and other organization
22.214.171.124 Promising pipeline for the treatment of cystic fibrosis
126.96.36.199 Market expansion opportunities in emerging nations
5.1.4 DRO - Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.2 CFTR Modulators
6.5 Pancreatic Enzyme Supplements
7 Route of Administration: Market Size and Analysis
7.2 Oral 7.3 Inhalation
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendors Profile
10.2 F. Hoffmann-La Roche
10.3 Gilead Sciences, Inc.
10.4 Vertex Pharmaceuticals
11 Companies to Watch for
11.1 Advanced Inhalation Therapies (AIT) Ltd.
11.2 Alcresta Therapeutics, Inc.
11.3 Allergan Plc
11.5 Merck & Co. Inc
For more information about this report visit https://www.researchandmarkets.com/r/p8ry5t
View source version on businesswire.com:https://www.businesswire.com/news/home/20191011005167/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 10/11/2019 05:11 AM/DISC: 10/11/2019 05:11 AM